

Global Liquid Biopsy Market: By Products and Services (Instruments, Reagents, and Services & Software), By Biomarker Type (Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes, and Others), By Sample Type (Blood Samples, Urine Samples, and Other Biofluid Samples), By Application (Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Leukemia, Lung Cancer, Prostate Cancer, and Other Cancers), By Analysis Method (Multi - gene - parallel Analysis and Single Gene Analysis (PCR Microarrays)), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G7496837A72EN.html>

Date: September 2017

Pages: 197

Price: US\$ 4,400.00 (Single User License)

ID: G7496837A72EN

Abstracts

Global Liquid Biopsy Market Report Description:

Global liquid biopsy market report gives comprehensive outlook on liquid biopsy products and services across the globe with special emphasis on key regions such as

Global Liquid Biopsy Market: By Products and Services (Instruments, Reagents, and Services & Software), By Bio...

North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on liquid biopsy market gives historical, current, and future market sizes (US\$ Mn) on the basis of product & services type, biomarker type, sample type, application, analysis method, end user, and geographic regions. This report studies liquid biopsy market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, liquid biopsy market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed liquid biopsy market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the liquid biopsy market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and usage of liquid biopsy products and services.

Global Liquid Biopsy Market:

Global liquid biopsy market estimated to be valued US\$ 734 Mn in 2017 and poised to grow at CAGR of 21.4% over 2017-2023. Market for liquid biopsy projected to reach US\$ 2345 Mn by 2023 owing to growing need for effective and non-invasive cancer diagnostic tools.

Trusted alternative to conventional cancer screening method

Global liquid biopsy market is gaining traction in recent times owing to its accurate, effective results in comparison with traditional cancer screening methods, which are achieved through minimal invasiveness and expenses. Challenges associated with traditional biopsy such as invasiveness, ill informed results, post sampling medical challenges and costs are prompting the healthcare professionals to adopt less invasive liquid biopsy tests for cancer screening and management, which is projected to create significant market demand for liquid biopsy products and services over the forecast period. Moreover, several clinical research activities related to liquid biopsy biomarkers are in late stage and it is expected that, upon successful launch and commercialization of these tests over the forecast period will result into significant market growth.

Growing investment in liquid biopsy products R&D and commercialization is projected to drive the market revenue growth

Players in the global liquid biopsy market increasingly attracting the investments in

recent times for development and commercialization of late stage products through IPOs. For instance, RainDance Technologies and Biocept filled IPOs in 2015 and 2014 respectively to develop advanced liquid biopsy technologies to aid physicians to devise suitable treatment strategies. Moreover, growing awareness among key stakeholders regarding liquid biopsy assays expected to drive market demand for these tests over the forecast period across the globe.

North America emerged as prominent region for liquid biopsy market across the globe

North America market expected to hold the higher revenue share in global liquid biopsy market and projected to remain same over the forecast period owing to accessibility, availability of advanced diagnostic tools such as liquid biopsy in the region. Asia-pacific liquid biopsy market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to large medical unmet need in the region.

COMPETITION ASSESSMENT

Key players profiles in the global Liquid Biopsy market include:

Biocept Inc. (U.S)

Bio-Rad Laboratories Inc. (U.S)

Fraunhofer-Gesellschaft (Germany)

Guardant Health, Inc. (U.S)

Janssen Diagnostics, LLC (U.S)

MDxHealth SA (U.S)

Myriad Genetics (U.S)

QIAGEN (Netherlands)

RainDance Technologies, Inc. (U.S)

Roche (Switzerland)

Trovagene Inc. (U.S)

Players in liquid biopsy market are focusing on development and commercialization of late stage tests through investigative and observational studies to garner larger market revenue share in global liquid biopsy market

KEY FINDINGS OF THE REPORT:

Global liquid biopsy market expanding at 21.4% CAGR over 2017 to 2023 to reach market value of US\$ 2345 Mn by 2023

Based on biomarker type, Circulating Tumor DNA (ctDNA) expected to emerge as larger revenue generating segment end of the forecast period owing to numerous late stage pipeline clinical trials for ctDNA

Blood samples are prominent source for liquid biopsy tests and accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period

Players are focusing on developing technologically advanced tests to detect the biomarkers

KEY FEATURES OF THE REPORT:

The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)

The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies

The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

The report tracks recent innovations, key developments and startup's details that are actively working in the market

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Products and Services

Instruments

Reagents

Services and Software

By Biomarker Type

Circulating Tumor Cells (CTC)

Circulating Tumor DNA (ctDNA)

Exosomes

Others

By Sample Type

Blood Samples

Urine Samples

Other Biofluid Samples

By Application

Breast Cancer

Colorectal Cancer

Gastrointestinal Cancer

Leukemia

Lung Cancer

Prostate Cancer

Other Cancers

By Analysis Method

Multi - gene - parallel Analysis (NGS)

Single Gene Analysis (PCR Microarrays)

By End User

Hospitals

Diagnostic Laboratories

Academic and Research Institutes

By Geography

North America

U.S

Canada

Europe

Germany

France

U.K

Italy

Spain

Russia

Poland

Rest of Europe

Asia-Pacific

Japan

China

India

Australia & New Zealand

ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia,
and Others)

South Korea

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Argentina

Venezuela

Rest of Latin America

Middle East and Africa (MEA)

Gulf Cooperation Council (GCC) Countries

Israel

South Africa

Rest of MEA

Contents

1. RESEARCH METHODOLOGY

- 1.1. Secondary and Primary research
 - 1.1.1. Secondary Sources
 - 1.1.2. Primary Sources
- 1.2. Market Revenue Estimation Methodology
- 1.3. Key Assumptions
- 1.4. Acronyms

2. SCOPE OF STUDY

- 2.1. Market Definition
- 2.2. Objective of the Research
- 2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL LIQUID BIOPSY MARKET DYNAMICS

- 4.1. Drivers
 - 4.1.1. Economic Drivers
 - 4.1.2. Demand Side Drivers
 - 4.1.3. Supply Side Drivers
- 4.2. Restraints
- 4.3. Opportunities/Unmet Needs of the Market
- 4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

- 5.1. Competition analysis
- 5.2. Regulatory landscape
- 5.3. PESTLE analysis
- 5.4. Porter's analysis

6. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY PRODUCTS AND SERVICES, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Instruments

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.2. Reagents

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.3. Services and Software

6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY BIOMARKER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Circulating Tumor Cells (CTC)

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7.2. Circulating Tumor DNA (ctDNA)

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7.3. Exosomes

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7.4. Others

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY SAMPLE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Blood Samples

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8.2. Urine Samples

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8.3. Other Biofluid Samples

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Breast Cancer

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.2. Colorectal Cancer

9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.3. Gastrointestinal Cancer

9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.4. Leukemia

9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.5. Lung Cancer

9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.6. Prostate Cancer

9.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.7. Other Cancers

9.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY ANALYSIS METHOD, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Multi - gene - parallel Analysis (NGS)

10.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10.2. Single Gene Analysis (PCR Microarrays)

10.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

11. GLOBAL LIQUID BIOPSY MARKET FORECAST, BY END USER ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Hospitals

- 11.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
- 11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
- 11.2. Diagnostic Laboratories
 - 11.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
 - 11.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
- 11.3. Academic and Research Institutes
 - 11.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
 - 11.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

12. LIQUID BIOPSY MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. North America Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

- 12.1.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.1.1.1. Instruments
 - 12.1.1.2. Reagents
 - 12.1.1.3. Services and Software
- 12.1.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.1.2.1. Circulating Tumor Cells (CTC)
 - 12.1.2.2. Circulating Tumor DNA (ctDNA)
 - 12.1.2.3. Exosomes
 - 12.1.2.4. Others
- 12.1.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.1.3.1. Blood Samples
 - 12.1.3.2. Urine Samples
 - 12.1.3.3. Other Biofluid Samples
- 12.1.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.1.4.1. Breast Cancer
 - 12.1.4.2. Colorectal Cancer
 - 12.1.4.3. Gastrointestinal Cancer
 - 12.1.4.4. Leukemia
 - 12.1.4.5. Lung Cancer
 - 12.1.4.6. Prostate Cancer
 - 12.1.4.7. Other Cancers

12.1.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.1.5.1. Multi - gene - parallel Analysis (NGS)

12.1.5.2. Single Gene Analysis (PCR Microarrays)

12.1.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.1.6.1. Hospitals

12.1.6.2. Diagnostic Laboratories

12.1.6.3. Academic and Research Institutes

12.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.1.7.1. U.S.

12.1.7.2. Canada

12.2. Europe Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

12.2.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.1.1. Instruments

12.2.1.2. Reagents

12.2.1.3. Services and Software

12.2.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.2.1. Circulating Tumor Cells (CTC)

12.2.2.2. Circulating Tumor DNA (ctDNA)

12.2.2.3. Exosomes

12.2.2.4. Others

12.2.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.3.1. Blood Samples

12.2.3.2. Urine Samples

12.2.3.3. Other Biofluid Samples

12.2.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.4.1. Breast Cancer

12.2.4.2. Colorectal Cancer

12.2.4.3. Gastrointestinal Cancer

12.2.4.4. Leukemia

12.2.4.5. Lung Cancer

12.2.4.6. Prostate Cancer

12.2.4.7. Other Cancers

12.2.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.5.1. Multi - gene - parallel Analysis (NGS)

12.2.5.2. Single Gene Analysis (PCR Microarrays)

12.2.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.6.1. Hospitals

12.2.6.2. Diagnostic Laboratories

12.2.6.3. Academic and Research Institutes

12.2.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.2.7.1. U.K

12.2.7.2. Germany

12.2.7.3. France

12.2.7.4. Italy

12.2.7.5. Spain

12.2.7.6. Russia

12.2.7.7. Poland 12.2.7.8. Rest of Europe

12.3. Asia-Pacific Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

12.3.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.3.1.1. Instruments

12.3.1.2. Reagents

12.3.1.3. Services and Software

12.3.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.3.2.1. Circulating Tumor Cells (CTC)

12.3.2.2. Circulating Tumor DNA (ctDNA)

12.3.2.3. Exosomes

12.3.2.4. Others

12.3.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.3.3.1. Blood Samples

12.3.3.2. Urine Samples

12.3.3.3. Other Biofluid Samples

12.3.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.3.4.1. Breast Cancer

- 12.3.4.2. Colorectal Cancer
- 12.3.4.3. Gastrointestinal Cancer
- 12.3.4.4. Leukemia
- 12.3.4.5. Lung Cancer
- 12.3.4.6. Prostate Cancer
- 12.3.4.7. Other Cancers
- 12.3.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.3.5.1. Multi - gene - parallel Analysis (NGS)
 - 12.3.5.2. Single Gene Analysis (PCR Microarrays)
- 12.3.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.3.6.1. Hospitals
 - 12.3.6.2. Diagnostic Laboratories
 - 12.3.6.3. Academic and Research Institutes
- 12.3.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.3.7.1. Japan
 - 12.3.7.2. China
 - 12.3.7.3. India
 - 12.3.7.4. ASEAN
 - 12.3.7.5. Australia & New Zealand
 - 12.3.7.6. Rest of Asia-Pacific
- 12.4. Latin America Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
 - 12.4.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.4.1.1. Instruments
 - 12.4.1.2. Reagents
 - 12.4.1.3. Services and Software
 - 12.4.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.4.2.1. Circulating Tumor Cells (CTC)
 - 12.4.2.2. Circulating Tumor DNA (ctDNA)
 - 12.4.2.3. Exosomes
 - 12.4.2.4. Others
 - 12.4.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 12.4.3.1. Blood Samples
 - 12.4.3.2. Urine Samples

12.4.3.3. Other Biofluid Samples

12.4.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.4.4.1. Breast Cancer

12.4.4.2. Colorectal Cancer

12.4.4.3. Gastrointestinal Cancer

12.4.4.4. Leukemia

12.4.4.5. Lung Cancer

12.4.4.6. Prostate Cancer

12.4.4.7. Other Cancers

12.4.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.4.5.1. Multi - gene - parallel Analysis (NGS)

12.4.5.2. Single Gene Analysis (PCR Microarrays)

12.4.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.4.6.1. Hospitals

12.4.6.2. Diagnostic Laboratories

12.4.6.3. Academic and Research Institutes

12.4.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.4.7.1. Brazil

12.4.7.2. Mexico

12.4.7.3. Argentina

12.4.7.4. Venezuela

12.4.7.5. Rest of Latin America

12.5. Middle East & Africa (MEA) Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

12.5.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.1.1. Instruments

12.5.1.2. Reagents

12.5.1.3. Services and Software

12.5.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.2.1. Circulating Tumor Cells (CTC)

12.5.2.2. Circulating Tumor DNA (ctDNA)

12.5.2.3. Exosomes

12.5.2.4. Others

12.5.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.3.1. Blood Samples

12.5.3.2. Urine Samples

12.5.3.3. Other Biofluid Samples

12.5.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.4.1. Breast Cancer

12.5.4.2. Colorectal Cancer

12.5.4.3. Gastrointestinal Cancer

12.5.4.4. Leukemia

12.5.4.5. Lung Cancer

12.5.4.6. Prostate Cancer

12.5.4.7. Other Cancers

12.5.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.5.1. Multi - gene - parallel Analysis (NGS)

12.5.5.2. Single Gene Analysis (PCR Microarrays)

12.5.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.6.1. Hospitals

12.5.6.2. Diagnostic Laboratories

12.5.6.3. Academic and Research Institutes

12.5.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

12.5.7.1. Gulf Cooperation Council (GCC) Countries

12.5.7.2. Israel

12.5.7.3. South Africa

12.5.7.4. Rest of MEA

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Biocept Inc. (U.S)

13.2.2. Bio-Rad Laboratories Inc. (U.S)

13.2.3. Fraunhofer-Gesellschaft (Germany)

13.2.4. Guardant Health, Inc. (U.S)

- 13.2.5. Janssen Diagnostics, LLC (U.S)
- 13.2.6. MDxHealth SA (U.S)
- 13.2.7. Myriad Genetics (U.S)
- 13.2.8. QIAGEN (Netherlands)
- 13.2.9. RainDance Technologies, Inc. (U.S)
- 13.2.10. Roche (Switzerland)
- 13.2.11. Trovogene Inc. (U.S)

I would like to order

Product name: Global Liquid Biopsy Market: By Products and Services (Instruments, Reagents, and Services & Software), By Biomarker Type (Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes, and Others), By Sample Type (Blood Samples, Urine Samples, and Other Biofluid Samples), By Application (Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Leukemia, Lung Cancer, Prostate Cancer, and Other Cancers), By Analysis Method (Multi - gene - parallel Analysis and Single Gene Analysis (PCR Microarrays)), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G7496837A72EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7496837A72EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970